Core Insights - Iridex Corporation demonstrated continued revenue growth, operational efficiencies, and positive cash flow in its preliminary unaudited results for Q4 and full year 2025 [1][4] Fourth Quarter 2025 Results - Total revenue is expected to be between $14.6 million and $14.8 million, representing year-over-year growth of 15% to 17% compared to $12.7 million in the prior year quarter [8] - The company achieved positive cash flow in the fourth quarter [8] - Sold 15,800 Cyclo G6 probes, an increase from 13,300 in the prior year quarter [8] - Sold 44 Cyclo G6 Glaucoma Laser Systems, slightly down from 47 in the prior year quarter [8] Full Year 2025 Results - Total revenue is expected to be between $52.5 million and $52.7 million, reflecting year-over-year growth of 8% compared to $48.7 million in 2024 [8] - The company expects to achieve positive adjusted EBITDA for the full year 2025 [8] - Sold 57,700 Cyclo G6 probes, an increase from 55,400 in the prior year [8] - Sold 133 Cyclo G6 Glaucoma Laser Systems, up from 125 in the prior year [8] Company Overview - Iridex Corporation is a leader in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market [5] - The company's proprietary MicroPulse technology offers safe and effective treatment for sight-threatening eye conditions [5]

Core Insights - Iridex Corporation has announced preliminary unaudited operational and financial results for Q1 2025, indicating a stabilization of the business and improved financial condition following a strategic investment by Novel Inspiration International Co., Ltd [1][3] Financial Performance - Total revenue for Q1 2025 is expected to be between $11.8 million and $12.0 million, consistent with $11.8 million in the same quarter of 2024 [7] - The company sold approximately 13,900 Cyclo G6 probes in Q1 2025, an increase from 13,300 in the prior year quarter [7] - The sales of Cyclo G6 Laser Systems rose to approximately 24 units in Q1 2025, compared to 22 units in the prior year quarter [7] - Cash and cash equivalents as of March 29, 2025, were reported at $7.2 million [7] Strategic Outlook - The company aims to achieve breakeven or better performance at historical revenue levels despite external factors such as changes in tariff policies [3] - An investor call is scheduled for April 16, 2025, to discuss Iridex and Novel's strategic vision for the company [3] Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market, particularly for treating glaucoma and retinal diseases [4] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment for sight-threatening eye conditions [4] - Iridex products are distributed in over 100 countries, primarily through independent distributors [4]